(Nanoparticle-based Augmenting Immune Response and Inhibiting Suppressive Environment)
AIRISE-CoV™ is AIRISE™ delivering an antigen of SARS-CoV-2 virus (virus that causes COVID-19). AIRISE™ is capable of modulating immunosuppression and is anticipated to be an effective vaccine in immunocompromised, elderly, and healthy populations.
AIRISE-CoV™ induces antibodies against SARS-CoV-2 protein in serum of mice
Description: End-point titer (black arrows) represents the number of fold serum dilutions where SARS-CoV-2 binding antibodies are still detectable (4X background signal). The higher the titers, the higher the antibody level is. AIRISE-CoV™ elicited end-point titers of f 105 and 106 after first and second dose, which are very high compared to 102-105 by other leading COVID-19 vaccine candidates (e.g. mRNA-1273 by Moderna, ChAdOx1 nCoV-19 by AstraZeneca/Oxford, INO-4800 by Inovio, NVX-CoV2373 by Novavax).